References
- du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized Phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer15, 1234–1244 (2009).
- Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 6th Annual Report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet.95(Suppl. 1), 161–192 ( 2006).
- Du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95, 1320–1329 (2003).
- Du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin–paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux Pour l’Etude des Cancers Ovariens. J. Clin. Oncol.24, 1127–1135 (2006).
- Pfisterer J, Weber B, Reuss A et al. Randomized Phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl Cancer Inst.98, 1036–1045 (2006).
- Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol.9(3), 389–393 (1991).
- Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol.36(2), 207–211 (1990).
- Rustin GJ, van der Burg ME; on behalf of MRC and EORTC Collaborators. Early treatment of relapsed ovarian cancer based on CA125 level alone versus delayed treatment based on conventional clinical indicators: results of the randomized MRC OV05 and EORTC 55955 trials. J. Clin. Oncol.27(18S), (2009) (Abstract 1).
- Du Bois A, Meier W, Lueck HJ et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomized trial of the german Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann. Oncol.13, 251–257 (2002).
- Kristensen G, Kaern J, Baekelandt M et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: a NSGO study. J. Clin. Oncol.26S, (2008) (Abstract 5508).
- Meier W, du Bois A, Reuss A et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized Phase III trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group (AGO-OVAR). Gynecol. Oncol.114, 199–205 (2009).
- Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol.15(6), 2183–2193 (1997).
- Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a gynecologic oncology group study. Gynecol. Oncol.101(3), 436–440 (2006).
- Sehouli J, Stengel D, Oskay-Oezcelik G et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a Phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol.26, 3176–3182 (2008).
- Sehouli J, Oskay-Oezcelik G, Stengel D et al. Topotecan weekly versus routine 5-day schedule in patients with platinum resistant ovarian cancer (tower): a randomized, mutlicenter trial of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J. Clin. Oncol.27(18S), (2009) (Abstract 5553).
- Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
- Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. (25), 2811–2818 (2007).
- Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol.26, 890–896 (2008).
- Vergote I, Finkler N, del Campo J et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur. J. Cancer45, 2324–2332 (2009).
- Parmar M, Lederman JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet361, 2099–2106 (2003).
- Gonzalez-Martin AJ, Calvo E, Bover I et al. Randomized Phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann. Oncol.16(5), 749–755 (2005).
- Du Bois A, Luck HJ, Pfisterer J et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) ovarian cancer study group. Ann. Oncol.12(8), 1115–1120 (2001).
- Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol.24(29), 4699–4707 (2006).
- Du Bois A, Pfisterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective Phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-UT). Gynecol. Oncol.107(3), 518–525 (2007).
- Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Ann. Oncol.18(2), 263–268 (2007).
- Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol. Oncol.108(1), 90–94 (2008).
- Pujade-Lauraine E, Mahner S, Kaern J. et al.A randomized, Phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J. Clin. Oncol.27, 18s, (2009) (LBA5509).
- Monk BJ, Herzog T, Kaye S et al. A randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer. Ann. Oncol.19(S8), (2008) (Abstract LBA4).
- Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.25, 5165–5171 (2007).
- Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
- Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
- Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol.25, 5180–5186 (2007).
- Mok TS, Wu Yl, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. (2009).
- Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355(26), 2733–2743 (2006).
- Ledermann JA, Rustin GJ, Hackshaw A et al. A randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer. J. Clin. Oncol.27, 15S, (2009) (Abstract 5501).
- Harter P, Huober J, Pfisterer J et al. A Phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies. J. Clin. Oncol.25, 18S (2007) (Abstract 3561).
- Friedlander M, Hancock KC, Benigno B et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: final results of a Phase II study. Presented at the 33rd European Society for Medical Oncology (ESMO) Congress. Stockholm, Sweden, 12–16 September, 2008 (Abstract 6630).
- Wagner U, Du Bois A, Pfisterer J et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – a Phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol. Oncol.105(1), 132–137 (2007).
- Berek J, Taylor P, Mcguire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol.27(3), 418–425 (2009).
- Pfisterer J, Du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol.17(10), 1568–1577 (2006).
- Parsons SL, Kutarska E, Koralewski P et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a Phase II/III study. J. Clin. Oncol.25(18S), (2007) (Abstract 5520).
- Farmer H, Mccabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917–921 (2005).
- Audeh MW, Penson RT, Friedlander M et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol.27, 15S, (2009) (Abstract 5500).
- Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Du Bois A. The role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev. Anticancer Ther9(7), 917–922 (2009).